Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies

Figure 1

Schematics of the study. Patients with T-cell malignancies (TCMs) were divided into training (T-cell acute lymphoblastic leukemia; T-ALL) and validation (T-cell lymphoma; TCL) cohorts. Peripheral blood from T-ALL patients in the training cohort was collected for ribonucleic acid (RNA) extraction and quantitative real-time polymerase chain reaction (qRT-PCR) to detect the expression levels of CD5 and CD6. Then, the relationship between CD5 and CD6 with overall survival (OS) and co-expression of CD5/CD6 for risk stratification was analyzed. Finally, gene expression omnibus (GEO) datasets, acting as a validation cohort, were used to validate the results in the training cohort.